Cohn Matthew purchased $46K of TBBK

Cohn Matthew purchased 1,000 shares of Bancorp, Inc. (TBBK) at an average of $45.54 ($45.51–$45.55) across 2 trades on 2026-11-03.

Original reporting
SEC EDGAR · Cohn Matthew
Published Nov 4, 2026, 9:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TBBK
Neutral
high confidence
Mentioned
$TBBK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TBBKNeutralLow
01

Why it matters

The filing provides a fresh, primary disclosure of a modest insider buy, offering limited actionable insight.

02

Market read

Minor relevance; the trade is too small to move the stock significantly.

03

What to watch

Potential upcoming earnings or regulatory news could dominate price movement more than this small insider trade.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; director purchases are monitored for sentiment.

Company-level read

Ticker impact

$TBBKNeutralHigh confidence
Context

Director Matthew Cohn purchased 1,000 shares for $45,540, increasing his stake to 63,111 shares.

Expected impact

slight upward pressure as market prices in director's buy

Evidence & confidence

The transaction is a primary Form 4 filing, but the dollar amount is under $50k, limiting market impact.

Market effects

None significant; Bancorp operates in regional banking with limited sector ripple.

Minimal impact on US banking sector.

None

Counterpoint

The purchase may be routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Matthew Cohn

    Director of Bancorp, Inc.

  • Bancorp, Inc.

    Regional bank listed on NYSE under ticker TBBK.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TBBKMed

The Bancorp 3Q 2026: Revenue $175.88M, EPS $1.53 — 10-Q Summary

The Bancorp reported 3Q 2026 revenue of $175.88M and net income of $62.78M, up 0.7% and 14.3% YoY respectively. Growth in fintech fees and lower credit-loss provisions offset reduced net interest income. Fintech loans grew to 19.6% of the loan portfolio. The company plans to discontinue new SBL originations by year-end, incurring $4.3M in restructuring costs.

$TBBKMed

Bancorp (TBBK) Q3 2026 Earnings Call Transcript

The Bancorp (TBBK) reported Q3 2026 core EPS of $1.47, up 25% YoY. GDV grew 23%, fintech fees rose 19%. The company updated 2027 EPS guidance to $7-$7.20 and initiated 2028 guidance at $8-$8.20. Restructuring costs of $5M will reduce staff by 80, saving $14M annually. The Bancorp plans to discontinue SBL loans and reallocate resources to fintech initiatives. Tax credit strategy will lower the tax burden. The company maintained 2026 guidance of $5.95-$6.04 EPS and expects $200M in buybacks.

$TBBKMedAI 8/10

Bancorp Q3 Earnings Call Highlights

Bancorp (TBBK) reported Q3 earnings, highlighting cooperation with Chime on contract timelines and potential redeployment of capital. The company signed a new fintech lending relationship and expects higher spreads. Bancorp launched Finetics, its embedded-finance platform, and initiated restructuring, reducing 80 positions. Q3 core ROA was 2.42%, core ROE 34.7%, with average loans up 3.7% QoQ. Fintech fees grew 12.8% YoY, representing 30% of core revenue.